Patents Assigned to WARF Wisconsin Alumni Research Foundation
-
Publication number: 20130230552Abstract: The invention provides a recombinant biologically contained influenza virus that is a PB2 knockout virus, e.g., one that is useful to generate a multivalent vaccine, and methods of making and using that virus.Type: ApplicationFiled: August 24, 2012Publication date: September 5, 2013Applicant: WARF - Wisconsin Alumni Research FoundationInventors: Yoshihiro Kawaoka, Gabriele Neumann, Makoto Ozawa
-
Publication number: 20120003263Abstract: Vaccines comprising one or more recombinant raccoon pox viruses and methods of using those vaccines to immunize avians.Type: ApplicationFiled: December 4, 2009Publication date: January 5, 2012Applicant: WARF - Wisconsin Alumni Research FoundationInventors: Jorge E. Osorio, Keith P. Iams, Brock Adam Bakke, Shi-Hsia Hwa
-
Publication number: 20110263554Abstract: The invention provides methods to identify agents useful to prevent, inhibit or treat viral infections, e.g. filovirus infections, as well as compositions having one or more agents to prevent, inhibit or treat viral infection.Type: ApplicationFiled: November 6, 2009Publication date: October 27, 2011Applicant: WARF - Wisconsin Alumni Research FoundationInventors: Yoshihiro Kawaoka, Shinji Watanabe, Yasuko Hatta
-
Publication number: 20110236417Abstract: The invention provides a vaccine comprising an effective amount of an isolated recombinant influenza virus comprising a mutant M gene segment that is mutated so that upon viral replication the mutant M gene expresses a functional M1 protein and a mutant M2 protein with a deletion of the cytoplasmic tail and either lacking a transmembrane domain or having a mutated transmembrane domain.Type: ApplicationFiled: March 23, 2011Publication date: September 29, 2011Applicant: WARF - Wisconsin Alumni Research FoundationInventors: Shinji Watanabe, Tokiko Watanabe, Yoshihiro Kawaoka
-
Publication number: 20110110978Abstract: The invention provides a composition useful to prepare high titer influenza viruses, e.g., in the absence of helper virus, which includes internal genes from an influenza virus vaccine strain or isolate, e.g., one that is safe in humans, for instance, one that does not result in significant disease, and genes from vaccine seed virus isolates which include a HA gene segment with a HA2 sequence encoding a HA2 that confers enhanced growth in cells in culture, such as Vero cells.Type: ApplicationFiled: October 26, 2010Publication date: May 12, 2011Applicant: WARF- Wisconsin Alumni Research FoundationInventors: Yoshihiro Kawaoka, Taisuke Horimoto, Shin Murakami
-
Publication number: 20110081373Abstract: The invention provides an isolated attenuated recombinant influenza virus comprising a gene segment comprising a mutant NS2 protein gene, wherein the NS2 protein has at least two substitutions that do not substantially alter the in vitro replication of the virus but are associated with attenuation of the virus in vivo, wherein at least one of the substitutions is a substitution for glutamate.Type: ApplicationFiled: August 11, 2010Publication date: April 7, 2011Applicant: WARF - Wisconsin Alumni Research FoundationInventors: Yoshihiro Kawaoka, Hatice Akarsu, Kiyoko Iwatsuki-Horimoto
-
Publication number: 20100311956Abstract: The invention provides amphiphilic compounds and methods for manipulating membrane proteins. Compounds of the invention, for example, the compounds of Formulas I-XIX, can be prepared from readily available starting materials. The amphiphilic compounds can manipulate membrane protein at relatively low concentrations compared to many known detergents. The compounds can be used to aid the isolation of membrane proteins, for example, to aid their solubilization and/or purification. The compounds can also be used to aid the functional and structural determination of membrane proteins, including their stabilization and crystallization.Type: ApplicationFiled: March 24, 2010Publication date: December 9, 2010Applicant: WARF - Wisconsin Alumni Research FoundationInventors: Samuel Helmer Gellman, Pil Seok Chae, Brian Kobilka, Soren Rasmussen
-
Publication number: 20100203114Abstract: The invention provides 17 AAG encapsulated in micelle particles. The micelles can be comprised of safe poly(ethylene glycol)-block-poly(lactic acid) (PEG-PLA). A significant advantage of PEG-PLA as a carrier is that it is less toxic than Cremophor® EL or DMSO. Additionally, PEG-PLA micelles are easier to handle than DMSO and they do not possess foul odors, which is a problem associated with 17-AAG formulations currently in clinical trials. The invention also provides methods of preparing active agents encapsulated micelles and therapeutic methods of using the micelles and their corresponding formulations, such as for the inhibition of Hsp 90, and/or for the treatment of cancer.Type: ApplicationFiled: July 9, 2008Publication date: August 12, 2010Applicant: WARF - Wisconsin Alumni Research FoundationInventors: Glen S. Kwon, M. Laird Forrest, Neal M. Davies
-
Publication number: 20100179111Abstract: The invention provides compounds of formula I and compositions thereof. The invention further provides methods of using the compounds and compositions. The compounds of the invention can provide high affinity binding to sigma-1 receptors in a mammal. The compounds can exhibit selectivity for the sigma-1 receptor over the sigma-2 receptor. The compounds and compositions of the invention can also be used to treat conditions that involve the sigma-1 receptor, such as addiction, cardiovascular conditions, and cancer, for example, cancer of the breast, lung, prostate, ovarian, colorectal, or the CNS.Type: ApplicationFiled: November 18, 2009Publication date: July 15, 2010Applicant: WARF - Wisconsin Alumni Research FoundationInventors: Arnold E. Ruoho, Abdol R. Hajipour, Uyen B. Chu, Dominique A. Fontanilla
-
Publication number: 20090270598Abstract: The invention provides amphiphiles for manipulating membrane proteins. The amphiphiles can feature carbohydrate-derived hydrophilic groups and branchpoints in the hydrophilic moiety and/or in a lipophilic moiety. Such amphiphiles are useful as detergents for solubilization and stabilization of membrane proteins, including photosynthetic protein superassemblies obtained from bacterial membranes.Type: ApplicationFiled: April 8, 2009Publication date: October 29, 2009Applicant: WARF - Wisconsin Alumni Research FoundationInventors: Samuel Helmer Gellman, Pil Seok Chae, Philip D. Laible, Marc J. Wander
-
Publication number: 20090264676Abstract: The invention provides novel compounds and methods to carry out organocatalytic Michael additions of aldehydes to nitroethylene catalyzed by a proline derivative to provide ?-substituted-?-nitroaldehydes. The reaction can be rendered enantioselective when a chiral pyrrolidine catalyst is used, allowing for Michael adducts in nearly optically pure form (e.g., 96-99% e.e.). The Michael adducts can bear a single substituent or dual substituents adjacent to the carbonyl. The Michael adducts can be efficiently converted to protected ?2-amino acids, which are essential for systematic conformational studies of ?-peptide foldamers.Type: ApplicationFiled: March 23, 2009Publication date: October 22, 2009Applicant: WARF - Wisconsin Alumni Research FoundationInventors: Samuel Helmer Gellman, Yonggui Chi, Li Guo
-
Patent number: 7587253Abstract: A partial enumeration model predictive controller and method of predictive control for a multiple input, multiple output (MIMO) system, including providing a solution table with problem solutions to a model predictive control problem for the MIMO system over a partial parameter region; scanning the solution table for an optimal solution for current parameters; using the optimal solution to control the MIMO system when the optimal solution is in the solution table; and using an alternative solution to control the MIMO system when the optimal solution is not in the solution table.Type: GrantFiled: August 1, 2006Date of Patent: September 8, 2009Assignee: WARF (Wisconsin Alumni Research Foundation)Inventors: James B. Rawlings, Stephen J. Wright, Gabriele Pannocchia
-
Publication number: 20090203545Abstract: The invention provides a recombinant vector comprising a DNA segment having a synthetic origin of DNA synthesis that binds EBNA-1 and is capable of initiating DNA synthesis of sequences linked to the synthetic origin of DNA synthesis and maintaining the linked sequences when in the presence of EBNA-1. The synthetic origin of DNA synthesis comprises at least two binding sites for EBNA-1, wherein the two EBNA-1 binding sites are flanked by at least two half-binding sites for TRF2 or at least two binding sites for a protein that enhances the affinity of EBNA-1 for the synthetic origin of DNA synthesis. Further provided are host cells with the vector and methods of using the vector, for instance, ex vivo or in vivo.Type: ApplicationFiled: January 14, 2009Publication date: August 13, 2009Applicant: WARF-Wisconsin Alumni Research FoundationInventors: Scott Eugene Lindner, William M. Sugden
-
Patent number: 7091037Abstract: An isolated and purified DNA molecule encoding a DNA repair protein, p95, is provided, as is isolated and purified p95. Also provided are methods of detecting p95 and DNA encoding p95. The invention further provides p95 knock-out mice.Type: GrantFiled: April 18, 2001Date of Patent: August 15, 2006Assignee: WARF Wisconsin Alumni Research FoundationInventors: John H. J. Petrini, William Francis Morgan, Richard Scott Maser, James Patrick Carney
-
Patent number: 7074902Abstract: An isolated and purified DNA molecule encoding a DNA repair protein, p95, is provided, as is isolated and purified p95. Also provided are methods of detecting p95 and DNA encoding p95. The invention further provides p95 knock-out mice.Type: GrantFiled: January 10, 2002Date of Patent: July 11, 2006Assignees: WARF Wisconsin Alumni Research Foundation, University of CaliforniaInventors: John H. J. Petrini, William Francis Morgan, Richard Scott Maser, James Patrick Carney